GLP-1 Medications
Expert gastroenterology care for patients on Ozempic, Wegovy, Mounjaro, and Zepbound — managing nausea, gastroparesis, procedural safety, and dose optimization in Dallas–Fort Worth.
GLP-1 receptor agonists (Ozempic, Wegovy, Rybelsus) and dual GIP/GLP-1 agonists (Mounjaro, Zepbound) have transformed the treatment of obesity and type 2 diabetes. They also cause significant GI effects by design — and managing those effects well is a defining issue in modern gastroenterology.
GLP-1 agonists work in part by:
The same mechanisms that drive weight loss also create the GI symptoms patients experience. Most are dose-dependent and improve with slower titration, but some require active management.
The most common side effect — affecting up to 40% of patients, especially during dose escalation. Strategies that work: smaller meals, lower-fat meals, eating more slowly, adequate hydration, ginger, anti-emetics short-term, slower titration.
Less common but more concerning, especially if persistent. Persistent vomiting raises the question of gastroparesis and warrants GI evaluation.
Affects roughly 10–20% of patients. Manage with hydration, fiber, and osmotic agents (PEG, magnesium oxide). Avoid stimulant laxatives long-term when possible.
Less common than constipation. Usually self-limited and improves with continued use.
Expected — and often the desired effect. However, severe early satiety leading to inadequate nutrition warrants evaluation.
Slowed gastric emptying can worsen reflux. Optimize with smaller meals, avoiding late-night eating, head-of-bed elevation, and PPI/H2 blocker therapy as needed.
By design, GLP-1 agonists slow gastric emptying. In a subset of patients, this becomes symptomatic gastroparesis — characterized by persistent nausea, vomiting, bloating, early satiety, and weight loss beyond what's intended. Most cases improve with dose reduction or pause; persistent symptoms after discontinuation warrant gastric emptying study and a full GI evaluation.
Because GLP-1 agonists slow gastric emptying, residual stomach contents at the time of sedation can theoretically increase aspiration risk. The earlier 2023 ASA recommendation to hold weekly GLP-1s for a week before any sedated procedure was replaced in June 2024 by a multi-society clinical practice update from the American Society of Anesthesiologists, American Society for Gastrointestinal Endoscopy, American Gastroenterological Association, AASLD, IFSO, and ASMBS. The updated approach is individualized:
This guidance applies to weekly agents (Ozempic, Wegovy, Mounjaro, Zepbound) and daily agents (Rybelsus, Saxenda, Victoza) alike — the principle is symptom- and risk-based rather than blanket discontinuation.
Patients scheduling a colonoscopy in DFW should review GLP-1 timing with their GI office during pre-procedure planning.
A small absolute risk increase has been reported. Patients with prior pancreatitis or unexplained severe abdominal pain on GLP-1 therapy should be evaluated.
Rapid weight loss — including GLP-1-driven loss — increases gallstone risk. Patients with biliary symptoms (right-upper-quadrant pain, fatty food intolerance) should be evaluated with ultrasound.
GLP-1 agonists are emerging as one of the most effective therapies for MASH. Patients with concurrent fatty liver and obesity often benefit substantially. See the MASLD page for more.
Dr. Ramani sees patients across the Dallas–Fort Worth area. Send a message and his team will be in touch.
Connect with Dr. Ramani →